BFM
ELEV

Boothbay Fund Management’s Elevation Oncology ELEV Stock Holding History

Boothbay Fund Management’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-183,454
Closed -$47.5K – 1540
2025
Q1 		$47.5K Hold
183,454
– – ﹤0.01% 1284
2024
Q4 		$103K Sell
183,454
-39
-0% -$23 ﹤0.01% 1286
2024
Q3 		$110K Hold
183,493
– – ﹤0.01% 1451
2024
Q2 		$495K Buy
183,493
+144,117
+366% +$543K 0.01% 999
2024
Q1 		$202K Sell
39,376
-217,339
-85% -$704K ﹤0.01% 1332
2023
Q4 		$138K Hold
256,715
– – ﹤0.01% 1392
2023
Q3 		$170K Buy
256,715
+22,449
+10% +$22.7K ﹤0.01% 1465
2023
Q2 		$356K Buy
+234,266
New +$618K 0.01% 1240

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Boothbay Fund Management's ELEV Position: Q2 2025 in Review

Boothbay Fund Management sold out of Elevation Oncology (ELEV) in Q2 2025, closing a stake of 183,454 shares — an estimated $47.5K sold.

Boothbay Fund Management first reported a position in ELEV in Q2 2023 and held it in 8 quarters. The position peaked at $495K in Q2 2024. 65 funds tracked by Wall St. Rank hold ELEV as of Q2 2025.

  • Boothbay Fund Management reported no remaining Elevation Oncology position as of Q2 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 183,454 Elevation Oncology shares in Q2 2025, an estimated $47.5K.
  • Boothbay Fund Management first reported a position in Elevation Oncology in Q2 2023 and held it in 8 quarters.
  • Boothbay Fund Management's Elevation Oncology position peaked at $495K in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.